AAV-VEGF gene therapy (Integene)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameAAV-VEGF gene therapy (Integene)
Drug Alias NameDivar-ig (Integene)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionVascular endothelial growth factor gene transference
TargetsVascular endothelial growth factor
Therapy Area/IndicationsPeripheral Vascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIntegene Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIntegene Inc
Active IndicationsN/A
Inactive IndicationsPeripheral Vascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A